United Therapeutics Chairperson and CEO Martine A. Rothblatt Reports Sale of $5.56 Million in Common Shares
- United Therapeutics Chairperson and CEO Martine A. Rothblatt sold 9,500 common shares on Oct. 28, 2026.
- Sales occurred at weighted-average prices ranging from $583.5017 to $588.3913 per share.
- Rothblatt also exercised stock options for 9,500 common shares at $117.76 per share, leaving 138,410 stock options held indirectly through a trust.
- Following the transactions, the transacting trusts held 324,443 common shares; Rothblatt separately held 40,513 shares directly.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001106578-26-000174), on October 29, 2026, and is solely responsible for the information contained therein.